Divis Laboratories Ltd Sees Mixed Technical Signals Amid Price Momentum Shift

Price Momentum and Recent Market Performance

On 4 Feb 2026, Divis Laboratories Ltd (NSE: 509760) closed at ₹6,197.90, marking a 3.99% increase from the previous close of ₹5,960.30. The intraday range was ₹6,155.45 to ₹6,303.00, indicating strong buying interest. Despite this daily strength, the stock remains below its 52-week high of ₹7,077.70, while comfortably above its 52-week low of ₹4,941.70.

Comparatively, the stock’s returns over various periods show a mixed picture against the Sensex benchmark. Over the past week, Divis Labs marginally outperformed the Sensex with a 2.31% gain versus 2.30%. However, over one month and year-to-date periods, the stock underperformed, declining 2.75% and 3.08% respectively, compared to Sensex losses of 2.36% and 1.74%. Over longer horizons, Divis Labs has delivered robust returns, with a 5-year gain of 68.13% slightly ahead of the Sensex’s 66.63%, and an impressive 10-year return of 460.59% far exceeding the Sensex’s 245.70%.

Technical Trend Shift: From Bearish to Mildly Bearish

The technical trend for Divis Laboratories has shifted from a clear bearish stance to a mildly bearish one, signalling a potential easing of downward pressure but no definitive bullish reversal yet. This nuanced change is reflected in several key indicators:

• MACD (Moving Average Convergence Divergence): The weekly MACD remains bearish, indicating that short-term momentum is still weak. The monthly MACD, however, has improved to mildly bearish, suggesting some stabilisation in longer-term momentum.
• RSI (Relative Strength Index): Both weekly and monthly RSI readings currently show no clear signal, hovering in neutral zones. This implies the stock is neither overbought nor oversold, leaving room for directional movement.
• Bollinger Bands: Weekly Bollinger Bands indicate a mildly bearish stance, with price action near the lower band, signalling potential volatility. Conversely, the monthly Bollinger Bands are bullish, reflecting longer-term upward price pressure.
• Moving Averages: Daily moving averages remain bearish, with the stock trading below key averages such as the 50-day and 200-day moving averages. This suggests short-term selling pressure persists.
• KST (Know Sure Thing): Both weekly and monthly KST indicators are mildly bearish, reinforcing the cautious outlook on momentum.
• Dow Theory: Weekly data shows no clear trend, while monthly readings are mildly bearish, indicating uncertainty in the broader market context for the stock.
• On-Balance Volume (OBV): Both weekly and monthly OBV show no discernible trend, suggesting volume is not confirming price moves strongly in either direction.

These mixed signals highlight a stock in a consolidation phase, where short-term technicals remain weak but longer-term indicators hint at potential support. The downgrade in Mojo Grade from Hold to Sell on 1 Feb 2026 reflects this cautious stance, with a current Mojo Score of 43.0 and a Market Cap Grade of 1, signalling limited upside from a momentum perspective.

Implications for Investors and Market Outlook

Investors should note that while the recent price uptick is encouraging, the prevailing technical indicators counsel caution. The bearish daily moving averages and weekly MACD suggest that short-term momentum remains fragile. The absence of strong RSI signals further emphasises the lack of conviction in either direction.

Longer-term indicators such as the monthly Bollinger Bands and MACD provide a more optimistic view, indicating that the stock may be forming a base for a potential recovery. However, the mildly bearish KST and Dow Theory readings temper expectations, signalling that any upward move may be gradual and subject to volatility.

Given Divis Laboratories’ strong historical performance—outperforming the Sensex significantly over 3, 5, and 10 years—long-term investors may view current technical weakness as a potential buying opportunity, provided they are comfortable with near-term fluctuations.

Meanwhile, the downgrade to a Sell rating by MarketsMOJO reflects a more cautious stance, likely influenced by the mixed technical signals and recent underperformance relative to the benchmark over the short term.

Summary and Strategic Considerations

In summary, Divis Laboratories Ltd is navigating a complex technical landscape. The recent price momentum shift has not yet translated into a clear bullish trend, with key indicators presenting a blend of bearish and mildly bearish signals. The stock’s strong long-term fundamentals and historical outperformance provide a solid foundation, but short-term technical caution remains warranted.

For traders, the current environment suggests a wait-and-watch approach, monitoring for confirmation of trend reversals through improved MACD and moving average crossovers. Long-term investors might consider accumulating on dips, given the stock’s resilience and sector leadership in Pharmaceuticals & Biotechnology.

Ultimately, the downgrade to a Sell rating by MarketsMOJO on 1 Feb 2026 reflects the need for prudence amid uncertain momentum, despite the stock’s recent price gains and strong historical returns.

Unlock special upgrade rates for a limited period. Start Saving Now →